RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune Disease.
Jahagirdar R, Attwell S, Marusic S, Bendele A, Shenoy N, McLure KG, Gilham D, Norek K, Hansen HC, Yu R, Tobin J, Wagner GS, Young PR, Wong NCW, Kulikowski E.
Jahagirdar R, et al. Among authors: wagner gs.
Mol Pharmacol. 2017 Dec;92(6):694-706. doi: 10.1124/mol.117.110379. Epub 2017 Sep 29.
Mol Pharmacol. 2017.
PMID: 28974538